Re: Noel W. Clarke, Andrew J. Armstrong, Mototsugu Oya, et al. Efficacy and Safety of Olaparib Plus Abiraterone Versus Placebo Plus Abiraterone in the First-line Treatment of Patients with Asymptomatic/Mildly Symptomatic and Symptomatic Metastatic Castration-resistant Prostate Cancer: Analyses from the Phase 3 PROpel Trial. Eur Urol Oncol. In press. https://doi.org/10.1016/j.euo.2024.09.013
Update your browser to view ScienceDirect correctly.
Your technical details and browser version:
Request ID: 917af76ebaecfac2-LAX IP: 47.97.18.252 UTC time: 2025-02-25T22:00:08+00:00 Browser: Mozilla/5.0 (X11; U; Linux x86_64; en-US; rv:1.9.1.4) Gecko/20091030 Gentoo Firefox/3.5.4
Comments (0)